Fate Therapeutics Inc (NASDAQ:FATE) insider Bahram Valamehr sold 5,700 shares of the firm’s stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $20.69, for a total transaction of $117,933.00. Following the completion of the sale, the insider now directly owns 91,758 shares of the company’s stock, valued at approximately $1,898,473.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Bahram Valamehr also recently made the following trade(s):

  • On Tuesday, October 15th, Bahram Valamehr sold 6,200 shares of Fate Therapeutics stock. The stock was sold at an average price of $14.18, for a total transaction of $87,916.00.

Shares of FATE stock traded down $0.01 on Friday, hitting $21.94. The stock had a trading volume of 1,315,860 shares, compared to its average volume of 1,157,719. Fate Therapeutics Inc has a twelve month low of $12.59 and a twelve month high of $22.82. The firm has a market cap of $1.66 billion, a P/E ratio of -18.44 and a beta of 1.96. The company has a current ratio of 7.53, a quick ratio of 7.53 and a debt-to-equity ratio of 0.10. The company has a fifty day moving average price of $17.93 and a two-hundred day moving average price of $17.74.

Fate Therapeutics (NASDAQ:FATE) last announced its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Fate Therapeutics had a negative net margin of 900.24% and a negative return on equity of 48.94%. The firm had revenue of $2.43 million during the quarter, compared to analyst estimates of $1.75 million. During the same period last year, the firm earned ($0.31) EPS. Fate Therapeutics’s quarterly revenue was up 136.7% on a year-over-year basis. On average, analysts expect that Fate Therapeutics Inc will post -1.46 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the company. State Street Corp grew its holdings in shares of Fate Therapeutics by 11.6% in the 3rd quarter. State Street Corp now owns 2,710,736 shares of the biopharmaceutical company’s stock valued at $42,098,000 after buying an additional 282,710 shares during the period. Point72 Asset Management L.P. grew its holdings in shares of Fate Therapeutics by 98.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,180,089 shares of the biopharmaceutical company’s stock valued at $18,327,000 after buying an additional 586,589 shares during the period. Pictet Asset Management Ltd. grew its holdings in shares of Fate Therapeutics by 224.6% in the 3rd quarter. Pictet Asset Management Ltd. now owns 1,121,118 shares of the biopharmaceutical company’s stock valued at $17,411,000 after buying an additional 775,700 shares during the period. Redmile Group LLC grew its holdings in shares of Fate Therapeutics by 8.3% in the 3rd quarter. Redmile Group LLC now owns 11,216,809 shares of the biopharmaceutical company’s stock valued at $174,197,000 after buying an additional 857,143 shares during the period. Finally, Millennium Management LLC grew its holdings in shares of Fate Therapeutics by 1,812.8% in the 3rd quarter. Millennium Management LLC now owns 3,355,119 shares of the biopharmaceutical company’s stock valued at $52,105,000 after buying an additional 3,179,714 shares during the period. 97.60% of the stock is owned by institutional investors.

FATE has been the subject of a number of analyst reports. BidaskClub raised shares of Fate Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday. Wells Fargo & Co raised shares of Fate Therapeutics from a “market perform” rating to an “outperform” rating and set a $24.00 target price for the company in a report on Monday, December 9th. Zacks Investment Research lowered shares of Fate Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Mizuho lifted their target price on shares of Fate Therapeutics from $27.00 to $33.00 and gave the stock a “buy” rating in a report on Monday, December 30th. They noted that the move was a valuation call. Finally, Stifel Nicolaus initiated coverage on shares of Fate Therapeutics in a report on Monday, September 30th. They set a “buy” rating and a $27.00 target price for the company. Five equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $25.00.

About Fate Therapeutics

Fate Therapeutics, Inc operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system.

Further Reading: How is the LIBOR rate calculated?

Insider Buying and Selling by Quarter for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.